SUNITINIB - an oral drug used in the treatment of Renal Cell Carcinoma (RCC), Imatinib Resistant Gastrointestinal Stromal Tumor (GIST) and Pancreatic Neuroendocrine Tumor (pNET) is finally here in INDIA.
The drug has been launched under the dosage: 12.5mg, 25mg & 50mg.
SUNITINIB is already approved by the US Food And Drug Administration (US FDA) in the US.
SUNITINIB is an oral Multi-Kinase Inhibitor (MKI) which works by blocking several enzymes that promote uncontrolled cell growth in the body. It works by stopping or slowing the growth of cancer tumors. It may also slow the growth of new blood vessels within the tumor. This drug is already approved by the US Food And Drug Administration (US FDA) for use in the US.
Kidney cancer globally accounts for more than 131000 deaths each year and has been found to place a large economic loss on society. This type of cancer is among the top 10 most common cancers in both men and women.
The American Cancer Society has estimated that there will be about 75000 and more new cases of RCC (both including men and women) & Renal Pelvic Cancer together this year i.e. 2021.
The following are some common side effects:
- Fatigue
-Nausea and Vomiting
- Diarrhea
- Hypertension
- Heartburn
- Poor Apetite
- Weakness
The cost of 12.5mg SUNITINIB capsule in the US is approx USD 5000 for 28 capsules. This drug is now available in INDIA at a fraction of the above stated price. For more information please contact us: info.kahpro@gmail.com
Note: This is just a blog and is intended to offer free information online. For any advice on administration of any medicine, please consult your doctor.
No comments:
Post a Comment